PROSCA/BLADDR 2020 | Unmet needs in mHSPC

Ursula Vogl, MD, Ente Ospedaliero Cantonale (EOC), Ticino, Switzerland, outlines areas of unmet need in metastatic hormone-sensitive prostate cancer (mHSPC) including a better understanding of when to use targeted therapies, as well as identifying patients that are more likely to respond to therapies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).